echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Precisely eliminate harmful bacteria 32 million euros to help develop antibiotic alternative therapies

    Precisely eliminate harmful bacteria 32 million euros to help develop antibiotic alternative therapies

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, Micreos announced that it has received 32 million euros in funding to further develop its innovative endolysins technology platform
    The platform will not affect beneficial microorganisms like traditional antibiotics, but only target and kill harmful bacteria

    The funds received will also help Micreos advance its clinical development projects for the treatment of atopic dermatitis, diabetic foot ulcers and blood infections


    The microbiome in the human body is vital to body function and plays an important role in maintaining the stability of the immune system.
    However, the emergence of antibiotics has broken this balance

    Most antibiotics are "we do not distinguish between the enemy and the enemy".
    They will kill the beneficial and harmful bacteria in our body.
    Long-term abuse of antibiotics can easily cause imbalance of the flora in the body, reduce immunity, and develop drug resistance


    Micreos' strategy is to borrow endolysins produced by nature
    Endolysin is a compound released by phage to dissolve the cell wall from inside the bacteria

    It has a strong bactericidal ability and can target drug-resistant Staphylococcus aureus and other drug-resistant bacteria, destroy the cell wall of the bacteria, and cause the death of the bacteria

    Unlike antibiotics, these enzymes only kill specific strains, and their high specificity allows endolysin to kill only harmful bacteria without harming beneficial good bacteria


    ▲Bacteriophages use endolysin to destroy bacterial cell walls (picture source: reference [2])

    Among the two current lead drugs, XZ.
    700 targets to kill Staphylococcus aureus, including antibiotic-resistant methicillin-resistant Staphylococcus aureus (MRSA), while retaining the epidermis that is beneficial to the skin and conducive to wound healing Staphylococcus epidermidis

    800 can target all strains of Staphylococcus

    The clinical development plan of XZ.
    700 and SP.
    800 includes the following indications: atopic dermatitis, diabetic foot ulcer, blood infection, and skin T-cell lymphoma


    Reference materials:

    [1] Micreos secures €32 million for its endolysin-based platform as sustainable alternative to antibiotics.
    Retrieved September 30, 2021, from https:// -its-endolysin-based-platform-as-sustainable-alternative-to-antibiotics-301388573.

    [2] Murray et al.
    , (2021).
    The Advantages and Challenges of Using Endolysins in a Clinical Setting.
    Viruses, https://doi.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.